Thompson Davis & Co’s Cumberland Pharmaceuticals CPIX Stock Holding History

Thompson Davis & Co’s Portfolio CPIX Stock Details CPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,250	Closed	-$9K	–	643
2017 Q4	$9K	Buy	+1,250	New	+$9.2K	0.02%	427
2017 Q2	–	Sell	-200	Closed	-$1K	–	1094
2017 Q1	$1K	Sell	200 -2,000	-91%	-$12.1K	﹤0.01%	1100
2016 Q4	$12K	Buy	2,200 +2,000	+1,000%	+$10.4K	0.02%	639
2016 Q3	$1K	Hold	200	–	–	﹤0.01%	1055
2016 Q2	$1K	Hold	200	–	–	﹤0.01%	1007
2016 Q1	$1K	Sell	200 -16,450	-99%	-$78.4K	﹤0.01%	1004
2015 Q4	$88K	Sell	16,650 -15,000	-47%	-$85.5K	0.12%	175
2015 Q3	$183K	Sell	31,650 -14,350	-31%	-$89.4K	0.26%	98
2015 Q2	$329K	Buy	46,000 +11,850	+35%	+$82.4K	0.38%	50
2015 Q1	$227K	Buy	+34,150	New	+$213K	0.27%	84

Other funds holding CPIX

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thompson Davis & Co's CPIX Position: Q1 2018 in Review

Thompson Davis & Co sold out of Cumberland Pharmaceuticals (CPIX) in Q1 2018, closing a stake of 1,250 shares — an estimated $9K sold.

Thompson Davis & Co first reported a position in CPIX in Q1 2015 and held it in 10 quarters. The position peaked at $329K in Q2 2015. 29 funds tracked by Wall St. Rank hold CPIX as of Q1 2018.

Thompson Davis & Co reported no remaining Cumberland Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Thompson Davis & Co sold 1,250 Cumberland Pharmaceuticals shares in Q1 2018, an estimated $9K.
Thompson Davis & Co first reported a position in Cumberland Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Thompson Davis & Co's Cumberland Pharmaceuticals position peaked at $329K in Q2 2015.
29 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q1 2018.

Based on Thompson Davis & Co's 13F filing for Q1 2018, filed 2 May 2018.